BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

The Phase III Vital prostate cancer trial which were terminated prematurely did set back the GVAX program but allowed researchers to understand how to best use the GVAX vaccine. In the long run this may be a blessing. One of the take aways from the Vital trial was that the vaccines need time to react. Therefore GVAX works best on slower growing cancers or aggressive cancers that are detected early.

As better methods for early detection improve such as Nanotechnology For Detecting Diseases Earlier, the market for cancer vaccines such as GVAX will increase.

In the article Prevention and Early Detection of Cancer in the United States they suggest using vaccines as a method to prevent cancer. It makes sense that one day GVAX could be prescribed to people who have a family history of a given cancer, boosting their immune system to fight the cancer in its infancy. This would be in addition to the combination therapy presently being tested for those who are diagnosed with cancer.

When the above happens the target audience for GVAX vaccines will have grown significantly. This could end up being much bigger then any of us ever realized.